Lee Hong Yeul, Chung Soomin, Hyeon Dongwoo, Yang Hyun-Lim, Lee Hyung-Chul, Ryu Ho Geol, Lee Hyeonhoon
Department of Critical Care Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, Republic of Korea.
NPJ Digit Med. 2024 Nov 18;7(1):325. doi: 10.1038/s41746-024-01335-x.
Delirium can result in undesirable outcomes including increased length of stays and mortality in patients admitted to the intensive care unit (ICU). Dexmedetomidine has emerged for delirium prevention in these patients; however, optimal dosing is challenging. A reinforcement learning-based Artificial Intelligence model for Delirium prevention (AID) is proposed to optimize dexmedetomidine dosing. The model was developed and internally validated using 2416 patients (2531 ICU admissions) and externally validated on 270 patients (274 ICU admissions). The estimated performance return of the AID policy was higher than that of the clinicians' policy in both derivation (0.390 95% confidence interval [CI] 0.361 to 0.420 vs. -0.051 95% CI -0.077 to -0.025) and external validation (0.186 95% CI 0.139 to 0.236 vs. -0.436 95% CI -0.474 to -0.402) cohorts. Our finding indicates that AID might support clinicians' decision-making regarding dexmedetomidine dosing to prevent delirium in ICU patients, but further off-policy evaluation is required.
谵妄会导致不良后果,包括入住重症监护病房(ICU)的患者住院时间延长和死亡率增加。右美托咪定已被用于预防这些患者的谵妄;然而,最佳剂量的确定具有挑战性。本文提出了一种基于强化学习的谵妄预防人工智能模型(AID),以优化右美托咪定的给药剂量。该模型使用2416例患者(2531次ICU入院)进行开发和内部验证,并在270例患者(274次ICU入院)上进行外部验证。在推导队列(0.390 95%置信区间[CI] 0.361至0.420 vs. -0.051 95% CI -0.077至-0.025)和外部验证队列(0.186 95% CI 0.139至0.236 vs. -0.436 95% CI -0.474至-0.402)中,AID策略的估计性能回报均高于临床医生的策略。我们的研究结果表明,AID可能有助于临床医生在右美托咪定给药剂量决策中预防ICU患者的谵妄,但仍需要进一步的非策略评估。